Myosana Therapeutics

About Myosana Therapeutics

Myosana Therapeutics is pioneering a non-viral gene therapy platform aimed at transforming the treatment of neuromuscular and cardiac diseases. The company focuses on developing innovative solutions for genetic muscle diseases, overcoming limitations of viral delivery methods to expand the range of treatable conditions.

Products & Services

The Myosana Platform:A targeted non-viral gene therapy platform designed for neuromuscular and cardiac genetic diseases, addressing limitations of viral delivery methods.

Duchenne Muscular Dystrophy (DMD) Therapy:A therapy aimed at saving lives, increasing longevity, and improving quality of life for DMD patients using the Myosana platform.

X-Linked Myotubular Myopathy (MTM) Therapy:A treatment for a rare neuromuscular disorder caused by mutations in the myotubularin (MTM1) gene, associated with significant morbidity and early mortality.

Future Applications:Expanding the Myosana platform to treat a broad range of neuromuscular disorders and cardiomyopathies after initial focus on DMD.

Specialties

Non-viral gene therapy Neuromuscular diseases Cardiac genetic diseases Duchenne Muscular Dystrophy (DMD) X-Linked Myotubular Myopathy (MTM)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2023-01-25 FD: 2023-01-25	4 investors
2	RT: Venture Philanthropy Investment T: - FT: Venture Philanthropy Investment	A: 650000 MR: - FA: $650,000 FAN: 650000	D: 2023-01-25 FD: 2023-01-25	1 investors

Seed Latest

2023-01-25

$5.0M

4 investors (Pro only)

Venture Philanthropy Investment 2023-01-25

$650K

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeff Chamberlain

Professor of Neurology

J

Justin Fallon

Professor of Medical Science

LinkedIn (Pro only)

M

Monkel Lek

Assistant Professor of Genetics

LinkedIn (Pro only)

J

James Thompson

Head of CMC (Retired)

M

Matthew Lumley

Chief Executive Officer

N

Nick Whitehead

Founder & Chief Science Officer

View 9 more team members with Pro

Unlock Full Team Directory

Recent News